个人简介

栾晓东，助理教授（特聘研究员），博士/硕士研究生导师。曾获北京市科学技术进步一等奖。获得国家重点研发计划、国家自然科学基金、北京市自然科学基金等项目资助。 2023年加入北京协和医院，任转化医学国家重大科技基础设施药物研发与平台主任。

主要研究内容

长期致力于罕见病与常见病的疾病机制及共性调控机制研究；未来实验室将聚焦单细胞多组学整合解析与创新性靶点发现，依托靶点结构开展精准药物筛选与新药研发，着力推动基础研究向临床转化，为疾病精准诊疗与创新药物研发提供核心理论依据与关键技术支撑。

代表性成果

1.Luan Xiaodong#, Jin Ye#, Guan Liping#, Liu Peng, Feng Hailong, Zhang Dingding, Chen Jingdan, Liu Weida, Li Fangyuan, Wang Anqi, Zhao Kun, He Ruirui, Liu Hankui, Zhu Shida, Yang Shuang, Zhao Lijian, Wang Jian, Li Linkang, Guo Dan*, Zhang Jianguo* and Zhang Shuyang*. National-scale genomic diagnosis of rare diseases in China. Sci. Bull. 2025, 20(70): 3324-3328. (IF="21.1).

2.Li Jiaying#, Shi Xiaoxiao, Xu Jiatong, Wang Kaiyue, Hou Fangxing, Luan Xiaodong*, Chen Limeng*. Aldehyde Dehydrogenase 2 Lactylation Aggravates Mitochondrial Dysfunction by Disrupting PHB2 Mediated Mitophagy in Acute Kidney Injury. Adv. Sci. 2025, 12(8):2411943. (IF="14.1).

3.Ju Kaide#, Bai Fang#, Xu Youwei#, Li Qingao, Su Gengchen, Jin Ye, Chen Houzao*, Zhang Shuyang*, and Luan Xiaodong*. Structural Insights into Isovaleryl-Coenzyme A Dehydrogenase: Mechanisms of Substrate Specificity and Implications of Isovaleric Acidemia-Associated Mutations. Research, 2025, (8): 0661. (IF="10.9).

4.Jiang Mengting#, Xu Youwei#, Luan Xiaodong#, Wu Kai, Li Zhen, Xu H Eric*, Zhang Shuyang*, Jiang Yi*, Yin Wanchao*. Structural basis of the cysteinyl leukotriene receptor type 2 activation by LTD4. PNAS. 2025, 122(15):e2417148122. (IF="9.1).

5.Su Gengchen#, Xu Youwei, Chen Binxian, Ju Kaide, Jin Ye, Chen Houzao*, Zhang Shuyang* and Luan Xiaodong*. Structural and biochemical mechanism of short-chain enoyl-CoA hydratase (ECHS1) substrate recognition. Commun. Biol. 2025, 8(1): 619. (IF="5.8)."

6.Duan Jia#, Xu Peiyu#, Zhang Huibing#, Luan Xiaodong#, Yang Jiaqi, He Xinheng, Mao Chunyou, Shen Dandan, Ji Yujie, Cheng Xi, Jiang Hualiang, Jiang Yi, Zhang Shuyang*, Zhang Yan*, Xu H Eric*. Mechanism of hormone and allosteric agonist mediated activation of follicle stimulating hormone receptor. Nat. Commun. 2023, 14(1). (IF="15.8).

7.Duan Jia#, Xu Peiyu#, Luan Xiaodong#, Ji Yujie, He Xinheng, Song Ning, Yuan Qingning, Jin Ye, Cheng Xi, Jiang Hualiang, Zheng Jie, Zhang Shuyang*, Jiang Yi*, Xu H Eric*. Hormone- and antibody-mediated activation of the thyrotropin receptor. Nature. 2022, 609(7928):854. (IF= 69.504)（F1000）

8.Luan Xiaodong#, Li Xinming#, Li Yufan#, Su Gengchen#, Yin Wanchao, Jiang Yi, Xu Ning, Wang Feng, Cheng Wang, Jin Ye, Zhang Leike, Xu H Eric*, Xue Yi*, Zhang Shuyang*. Antiviral drug design based on structural insights into the Nterminal domain and C-terminal domain of the SARS-CoV-2 nucleocapsid protein. Sci. Bull. 2022, 67(22). (IF= 18.9)

9.Yin Wanchao#, Luan Xiaodong#, Li Zhihai#, Zhou Ziwei#, Wang Qingxing#, Gao Minqi, Wang Xiaoxi, Zhou Fulai, Shi Jingjing, You Erli, Liu Mingliang, Wang Qingxia, Jiang Yi, Jiang Hualiang, Xiao Gengfu, Zhang Leike*, Yu Xuekui*, Zhang Shuyang*, Xu H Eric*. Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin. Nat. Struct. Mol. Biol. 2021, 28(3). (IF= 17.313)（C100，ESI，F1000）

10.Yin Wanchao#, Mao Chunyou#, Luan Xiaodong#, Shen Dandan#, Shen Qingya#, Su Haixia#, Wang Xiaoxi, Zhou Fulai, Zhao Wenfeng, Gao Minqi, Chang Shenghai, Xie Yuanchao, Tian Guanghui, Jiang Hewei, Tao Shengce, Shen Jingshan, Jiang Yi, Jiang Hualiang, Xu Yechun*, Zhang Shuyang*, Zhang Yan*, Xu H Eric*. Structural basis for inhibition of the RNA dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science. 2020, 368(6498). (IF= 47.728)（C100，ESI，F1000）